Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas.
Ninety-eight different malignant adnexal tumors were analyzed for the presence of epidermal growth factor (EGF)-specific binding sites and binding parameters were calculated by Scatchard plot analysis [G. Scatchard, Ann. N.Y. Acad. Sci. 51, 660-672 (1949)]. Thirty-four biopsies were EGF receptor (EGF-R) positive with dissociation constants (KD) of 0.5-12 X 10(-9) M and binding capacities (Bmax) of 2-250 fmol/mg. One tumor had a KD of 60 X 10(-9) M and a Bmax of 1660 fmol/mg. The correlation of EGF-R status with clinical parameters showed no significant differences in primary, metastatic, or recurrent tumors, histological subtype, tumor differentiation, and tumor residual after primary surgery. As an inverse correlation, EGF-R-positive tumors are 39% and EGF-R-negative tumors 60% progesterone receptor positive. A response to chemotherapy was noticed in 50% of EGF-R-positive ovarian carcinomas with a mean survival time of patients of 28 months. The response rate of EGF-R negative ovarian carcinomas was 12% with a mean survival time of 16 months. Regarding the treatment schedule the major differences were noticed in the cis-platinum plus cyclophosphamide treatment group. These results suggest that the biology of ovarian carcinomas is influenced by growth factors and their receptors, which can be used as prognostic factors.
Bauknecht
T
T
Universitäts-Frauenklinik, Freiburg, Federal Republic of Germany.
Runge
M
M
Schwall
M
M
Pfleiderer
A
A
D000290:Adnexa Uteri; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D005833:Genital Neoplasms, Female / Q000032:analysis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000032:analysis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D011379:Prognosis
D066246:ErbB Receptors